Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results

Sep 15, 2018

Xiaoqian Cheng, Warren Rowe, Lawan Ly, Alexey Shashurin, Taisen Zhuang, Shruti Wigh,Giacomo Basadonna, Barry Trink, Michael Keidar, and Jerome Canady
Breast cancer is the most common cancer diagnosed among US women (excluding skin cancers)
and is the second leading cause of cancer death among women after lung cancer [1]. Triple-negative
breast cancer refers to the breast cancer phenotype which has an absence or low level expression of
estrogen, progesterone, and HER2 receptors [2]. It is known for its poor clinical outcome and lack
of effective targeted therapy because women with triple-negative breast cancer do not benefit from
endocrine therapy or trastuzumab. Chemotherapy is currently the mainstay of systemic medical
treatment [3]. Patients with triple-negative disease have a lower three-year survival rate following
chemotherapy than patients with breast cancers of other subtypes [4].

Cold atmospheric plasma (CAP) has been extensively studied for its biomedical use in various
fields such as surface decontamination [5], wound healing [6,7], dental treatment [8], allergen
destruction [9], HIV virus treatment [10] and among others [11]. In particular, the research of CAP as
a potential oncotherapeutic approach has thrived over the past decade and the mechanism is been
increasingly understood [12–16]. It is widely reported that CAP deactivated more than 20 types
of cancer in vitro by inducing apoptosis [17–19], cell cycle arrest [20–22], endoplasmic reticulum
stress [23,24] and DNA damage [25–27]. CAP has also been shown to significantly reduce tumor
volume in an in vivo murine model following s phase cell cycle arrest and apoptosis [28].